Aberrantly expressed FLT3 has been observed at high levels in a spectrum of hematologic malignancies, including 70% to 100% of AML, B-ALL, a fraction of T-Cell ALL, and CML in lymphoid blast crisis [31]; however, this is the first report that evaluated its potential role and association to B-ALL prognosis. Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.